|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM108858480 |
| 003 |
DE-627 |
| 005 |
20231222150109.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0363.xml
|
| 035 |
|
|
|a (DE-627)NLM108858480
|
| 035 |
|
|
|a (NLM)10964536
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Laux, I
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation
|b implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.09.2000
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2000 Academic Press.
|
| 520 |
|
|
|a Since CD28 costimulation is critical for T-cell activation, there is great interest in CD28 as a target for immuntherapeutic approaches. We show that stimulation of human CD4(+) and CD8(+) T-cells differs in their responsiveness to stimulation with anti-CD3/CD28-coated beads, as surrogate antigen-presenting cells. While the CD4(+) subset responded with sustained proliferation, CD8(+) T-cells grew for a limited period only and failed to produce IL-2 beyond the first few days in culture. This decrease is accompanied with an increased rate of apoptosis in CD8(+) T-cells despite Bcl-x(L) expression. The CD8(+) but not the CD4(+) subset developed a reversible double-positive phenotype during CD28 costimulation. This finding may have some bearing on the appearance of double-positive T-cells in human peripheral blood. This double-positive subset was shown to undergo a statistically significantly increase during aging in humans. Taken together, the above data have important implications for immunotherapy and immune senescence
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a CD28 Antigens
|2 NLM
|
| 650 |
|
7 |
|a HLA-DP Antigens
|2 NLM
|
| 700 |
1 |
|
|a Khoshnan, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tindell, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bae, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a June, C H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Effros, R B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nel, A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 96(2000), 3 vom: 01. Sept., Seite 187-97
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:96
|g year:2000
|g number:3
|g day:01
|g month:09
|g pages:187-97
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 96
|j 2000
|e 3
|b 01
|c 09
|h 187-97
|